A Diagnostics & Imaging Week
Imaging Diagnostic Systems (IMDS; Fort Lauderdale, Florida) reported signing a non-exclusive agreement with Neomedica d.o.o. Beograd (Belgrade, Serbia) to market the company's CT Laser Mammography (CTLM) system to the private and public healthcare sectors of Slovenia, Croatia, Serbia, Montenegro, and Macedonia.
IMDS also said that Socrate Medical (Milan, Italy), has been selected as a distributor for the CTLM system in Northern and Central Italy. The company will market the system to the private and public sector of these regions.
The CTLM system is a breast imaging system that utilizes continuous wave laser technology and patented algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. Designed to be used in conjunction with mammography, CTLM reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.
Neomedica d.o.o. Beograd was founded in 1984 in Belgrade, Serbia, and shortly thereafter expanded by adding four sister companies located in Croatia, Slovenia and Macedonia as a result of the increasing demand for innovative medical technologies throughout these regions.
The company holds ISO 9001:2000 and SA 8000 certificates, and is the first company in Serbia with such certification.
"For the past 20 years, we have established strong relationships with key opinion leaders in the medical field. We are currently investing in organizing awareness and training to the prestigious university clinics, giving doctors the opportunity to learn new procedures," said Nikola Markovic, Neomedica deputy director. "There is an increasing demand for new technologies and products such as the CTLM system. With our experience and know-how in the introduction of new products and technologies, particularly in oncology, radiology, and surgery markets, we would like to expand our portfolio and be the first to introduce CTLM in our territories."
GHG buys St. Luke's Hospital
General Healthcare Group (GHG: London) has acquired St. Luke's Hospital in Fitzroy Square, Central London, as part of its expanding BMI Healthcare portfolio. The 16-bed hospital will now be named BMI Fitzroy Square Hospital and will be operated as a satellite of BMI London Independent Hospital in Stepney Green.
St Luke's Hospital has a major and minor operating theatre and eight consulting rooms, and facilities are at an exemplary standard following a £3.7 million refurbishment programme in 2007. Originally founded in 1907 as a charity providing medical care to the Clergy, the Charity's Trustees have decided to sell the hospital and move its clergy medical services to a location closer to the parishes they serve.
Adrian Fawcett, chief executive of General Healthcare Group, said, "We are delighted to welcome BMI Fitzroy Square Hospital to BMI Healthcare. The facilities and surgical expertise will provide great benefits to the Central London community, increasing accessibility for patients and consultants who spend most of their time in the city center."
The introduction of BMI Fitzroy Square is the latest in a string of recent acquisitions BMI Healthcare has made in Central London thus far this year. Earlier this quarter, BMI acquired City Medical, a facility in the heart of the city and near to London's Liverpool Street station that offers consultant-led outpatient and private GP services.
BMI also opened the Marylebone Consulting Rooms at Alliance Medical Imaging Centre in Westminster, providing private consulting and diagnostic imaging services for commuters, corporate employees, residents and tourists and is operated as a satellite unit of BMI The Clementine Churchill Hospital in Harrow.
BMI Healthcare provides acute-care private patient hospitals and outpatient centers in more than 60 UK locations .
Spain distribution deal for PLC
PLC Systems (Franklin, Massachusetts) said it has entered into a five year exclusive agreement with IZASA Distribuciones Tecnicas (Barcelona, Spain) for distribution of its RenalGuard System into that country
PLC said IZASA is one of Spain' leading distributors of interventional cardiology-related medical devices, and a part of the Werfen Group. It will target early adopters who recognize the benefits of utilizing the fluid-balancing capabilities of PLC's RenalGuard in a cath lab setting during cardiovascular imaging procedures for patients at higher risk of contrast-induced nephropathy (CIN).
PLC President/CEO Mark Tauscher said, "We are . . . pleased with our new agreement with IZASA in Spain. This firm's strong penetration of the leading cardiovascular centers in Spain will help expose the benefits of RenalGuard to a wider community of physicians."
PLC received the CE mark for the RenalGuard System in December 2007. An investigator-sponsored randomized clinical trial to evaluate the use of RenalGuard in the prevention of contrast-induced nephropathy is under way in Italy.